• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

‘Nightmare bacteria’ swarming the country, CDC reports

April 4, 2018 By Sarah Faulkner

CDCLast year, the Centers for Disease Control and Prevention identified more than 200 cases of bacteria that could resist nearly all antibiotics, the agency reported today.

The CDC said that these “nightmare bacteria” are resistant to all or most antibiotics and are making their way through the country. In one assessment, a lab discovered that 1 in 4 germ samples had a gene that enabled them to spread their resistance to other germs.

“Resistance genes with the capacity to turn regular germs into nightmare bacteria have been introduced into many states, but with an aggressive response, we’ve been able to stomp them out promptly,” CDC’s principal deputy director, Anne Schuchat, told The Hill.

“As fast as we have run to slow [antibiotic] resistance, some germs have outpaced us,” she said. “We’ve had some success, but it isn’t enough to turn the tide. We need to do more and we need to do it faster and earlier.”

The agency noted that it’s “not currently possible” to stop new resistance from developing, as germs are constantly evolving and finding ways to resist antibiotics.

The problem of antibiotic-resistant bacteria is not a theoretical one – at least 23,000 Americans die annually from infections due to resistant germs, according to the CDC.

The agency’s containment strategy involves quickly identifying resistance and testing asymptomatic patients who may be carrying, and therefore spreading, the resistant germ.

“The strategy requires a coordinated response among health care facilities, labs, health departments and CDC through the AR Lab Network. Health departments using the approach have conducted infection control assessments and colonization screenings within 48 hours of finding unusual resistance and have reported no further transmission during follow-up over several weeks,” the CDC said in a release.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Hospital Care, Pharmaceuticals Tagged With: Centers for Disease Control & Prevention

IN CASE YOU MISSED IT

  • Enable Injections, Sanofi obtain approval for on-body myeloma therapy in Japan
  • Abbott sets Libre Duo glucose-ketone sensor US launch for December
  • Sequel Med Tech’s automated twiist pump scores FDA clearance in type 2 diabetes
  • MiniMed completes split from Medtronic
  • Insulet’s Omnipod Discover data platform begins full US rollout

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS